421 related articles for article (PubMed ID: 23136242)
1. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.
van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann RM; Furst DE; Tyson N; Collinson N; Lehane PB
Ann Rheum Dis; 2013 Sep; 72(9):1496-502. PubMed ID: 23136242
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
3. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.
van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann R; Furst DE; Macey K; Sweetser M; Kelman A; Rao R
J Rheumatol; 2010 Mar; 37(3):558-67. PubMed ID: 20110520
[TBL] [Abstract][Full Text] [Related]
4. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.
van Vollenhoven RF; Fleischmann RM; Furst DE; Lacey S; Lehane PB
J Rheumatol; 2015 Oct; 42(10):1761-6. PubMed ID: 26276965
[TBL] [Abstract][Full Text] [Related]
5. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients.
Genovese MC; Breedveld FC; Emery P; Cohen S; Keystone E; Matteson EL; Baptiste Y; Chai A; Burke L; Reiss W; Sweetser M; Shaw TM
Ann Rheum Dis; 2009 Dec; 68(12):1894-7. PubMed ID: 19155233
[TBL] [Abstract][Full Text] [Related]
6. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
[TBL] [Abstract][Full Text] [Related]
7. Safety of rituximab in rheumatoid arthritis.
Covelli M; Sarzi-Puttini P; Atzeni F; Macchioni P
Reumatismo; 2010; 62(2):101-6. PubMed ID: 20657886
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).
Emery P; Deodhar A; Rigby WF; Isaacs JD; Combe B; Racewicz AJ; Latinis K; Abud-Mendoza C; Szczepanski LJ; Roschmann RA; Chen A; Armstrong GK; Douglass W; Tyrrell H
Ann Rheum Dis; 2010 Sep; 69(9):1629-35. PubMed ID: 20488885
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
Emery P; Mease PJ; Rubbert-Roth A; Curtis JR; Müller-Ladner U; Gaylis NB; Williams S; Reynard M; Tyrrell H
Rheumatology (Oxford); 2011 Dec; 50(12):2223-32. PubMed ID: 21926153
[TBL] [Abstract][Full Text] [Related]
11. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
12. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
[TBL] [Abstract][Full Text] [Related]
14. [Safety of rituximab in patients with rheumatoid arthritis].
Morović-Vergles J
Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.
Mariette X; Rouanet S; Sibilia J; Combe B; Le Loët X; Tebib J; Jourdan R; Dougados M
Ann Rheum Dis; 2014 Aug; 73(8):1508-14. PubMed ID: 23723317
[TBL] [Abstract][Full Text] [Related]
16. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
[TBL] [Abstract][Full Text] [Related]
17. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections.
Isvy A; Meunier M; Gobeaux-Chenevier C; Maury E; Wipff J; Job-Deslandre C; Kahan A; Allanore Y
Joint Bone Spine; 2012 Jul; 79(4):365-9. PubMed ID: 22285615
[TBL] [Abstract][Full Text] [Related]
18. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis.
Shi Y; Wu Y; Ren Y; Jiang Y; Chen Y
Int J Rheum Dis; 2019 Aug; 22(8):1361-1370. PubMed ID: 31099191
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
Kremer JM; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Westhovens R; Li T; Zhou X; Becker JC; Aranda R; Peterfy C; Genant HK
Ann Rheum Dis; 2011 Oct; 70(10):1826-30. PubMed ID: 21893583
[TBL] [Abstract][Full Text] [Related]
20. B-cell therapies in established rheumatoid arthritis.
Leandro MJ; Becerra-Fernandez E
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]